Differentiating pharmacologic agents used in catheter-directed thrombolysis. - Wikidata - wikimedia - TriplyDB

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

http://www.wikidata.org/entity/Q34563249

about

Review of pharmacology and physiology in thrombolysis interventions.Outcomes of catheter-directed treatment of lower extremity deep vein thrombosis of patients presenting to a tertiary care hospital

P2860

Q35882918-CE5FE1E2-8AF9-41F6-B206-3702CDDD630B Q36743266-9B01725B-0208-4E5D-9F12-C7C21827A4E9

P2860

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

http://www.wikidata.org/entity/Q34563249

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@ast

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@en

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@nl

type

label

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@ast

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@en

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@nl

prefLabel

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@ast

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@en

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@nl

P1433

Q34563249-A9C0A7DA-DF44-4FBB-A217-E97B4B6B3B98

P1476

Q34563249-B627B9C1-9E8A-46EC-88F5-3348510EFA36

P2093

Q34563249-265DB9D2-6E98-4467-9E72-EFD600196434

Q34563249-7124B71E-FCCB-448E-9AB2-448B1EF41697

P2860

Q34563249-12C8CEBB-22CE-482E-BAE0-C51E1F255F10

Q34563249-21C902FF-E121-47C9-8096-70019E1B589E

Q34563249-25945329-6D67-4C8D-A82C-4816CA2DFA48

Q34563249-2EF34949-D7AF-4989-8079-3718CD84483B

Q34563249-3EFAA0E6-14E7-4868-B064-4C6272261F5F

Q34563249-4499D45D-9285-41DB-B97D-46B22F377C2E

Q34563249-5D22355C-ECCC-4B85-844A-24508C3EC113

Q34563249-64C0123E-8A6B-420F-9049-FF0C53543C29

Q34563249-74219622-6812-4398-8A70-523FE4FC2D15

Q34563249-7570635B-6827-4441-84C4-214203E004E4

P304

Q34563249-78D0A74E-0E92-471A-A1C7-B0F269AF6C54

P31

Q34563249-06E89837-2DE5-4138-B36F-099B462EE1A4

P356

Q34563249-70DE27EF-2221-4DDA-9CBD-B00A90CC3E36

P433

Q34563249-04F1A7F5-654D-40EF-A8CB-A19BB7F7126B

P478

Q34563249-4061CF87-7A49-4A23-9EE1-3839DB57F746

P577

Q34563249-B0CF07CD-D1BB-4753-B171-714E97169648

P5875

Q34563249-AFA52756-E5B3-46D1-AFE0-B71123F4B7D4

P698

Q34563249-146AE969-7D30-4929-B7B5-00F6E27B0DC4

P921

Q34563249-35E804F5-AD5E-40F9-95D8-2C4CF1E64B16

Q34563249-D5FA9F6E-55F4-4AAB-B22E-4DD7FEA1E808

P932

Q34563249-DF0CEF11-2CAE-4B68-8968-8FA2F52FA678

P356

P1433

Seminars in interventional radiology

P1476

Differentiating pharmacologic agents used in catheter-directed thrombolysis.

@en

P2093

H Bob Smouse

http://www.w3.org/2001/XMLSchema#string

James L Swischuk

http://www.w3.org/2001/XMLSchema#string

P2860

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group

Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.

Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

Reteplase: a new thrombolytic for the treatment of acute myocardial infarction.

Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy.

Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.

Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.

The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.

P304

121-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1055/S-2005-871867

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49841306

http://www.w3.org/2001/XMLSchema#string

P698

21326682

http://www.w3.org/2001/XMLSchema#string

P921

catheterization

P932

3036270

http://www.w3.org/2001/XMLSchema#string